---
document_datetime: 2024-03-06 16:13:43
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/apealea-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: apealea-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.0314432
conversion_datetime: 2025-12-26 09:32:16.728318
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                               | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                               |
|----------------------|-----------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0017               | Renewal of the marketing authorisation.                                                             | 20/07/2023                                  | 11/09/2023                                  | SmPC, Labelling and PL           | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Apealea in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IA/0018              | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the | 03/04/2023                                  | n/a                                         |                                  |                                                                                                                                                                                                                                                                       |

Apealea Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                              |            |               |                        |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------|-----------------------------------|
| IB/0016            | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                                                                      | 08/11/2022 | n/a           |                        |                                   |
| IB/0015            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                            | 09/09/2022 | 24/03/2023    | SmPC and PL            | authorised                        |
| PSUSA/2264/ 202112 | Periodic Safety Update EU Single assessment - paclitaxel                                                                                                                                                                                                                                                  | 01/09/2022 | n/a           |                        | PRAC Recommendation - maintenance |
| IAIN/0013          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing product                                                            | 11/03/2022 | 24/03/2023 no | Annex II and PL longer |                                   |
| T/0012             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                       | 04/11/2021 | 09/12/2021    | SmPC, Labelling and PL |                                   |
| IA/0011            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                             | 16/03/2021 | n/a           |                        |                                   |
| IA/0010/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient Medicinal | 20/11/2020 | n/a           |                        |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0009/G | This was an application for a group of variations. B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) 28/05/2020 n/a longer                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0008/G | This was an application for a group of variations. B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its 10/04/2020 n/a Medicinal product no |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | corresponding test method B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test product   |            | no         | longer authorised   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|
| IAIN/0007 | procedure B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 18/02/2020 | n/a        |                     |
| IB/0006   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 04/02/2020 | 13/08/2020 | SmPC                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                    | (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |               |                    |                                                                                                                                                      |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2264/ 201812 | Periodic Safety Update EU Single assessment - paclitaxel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 25/07/2019 | 01/10/2019    | SmPC and PL longer | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2264/201812. authorised |
| II/0003/G          | This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.c.4.b - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient excipient - The specifications are affected or there is a change in physico-chemical properties of the excipient which may affect the quality of the FP B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test Medicinal product | 19/09/2019 | 13/08/2020 no | SmPC and PL        |                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                        |            |               | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0004     | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                            | 02/04/2019 | n/a           | longer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0001     | Update of section 5.1 of the SmPC in order to present post-hoc analyses of efficacy results for patients with first relapse in accordance with the approved indication. In addition, the Marketing authorisation holder (MAH) took the opportunity to correct minor typographical errors in the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal product | 14/03/2019 | 01/10/2019 no | In the ITT population of the pivotal efficacy study, the hazard ratios for PFS in the subgroups of patients with first relapse and second relapse were 0.80 (95% CI: 0.66;0.97) and 1.04 (95% CI: 0.74;1.47), respectively. The hazard ratios for OS in patients with first and second relapse were 0.98 (95% CI: 0.79;1.21) and 1.18 (95% CI: 0.79;1.75), respectively. Thus, the results in the subgroup of patients with first relapse are consistent with the results in the overall population and in addition, there was an indication of PFS benefit for Apealea. For more information, please refer to the Summary of Product Characteristics. |
| IAIN/0002/G | This was an application for a group of variations. B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished                                                                                                                                                                                                                                                                                   | 04/03/2019 | n/a           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->